Drug Sponsors

Novo Nordisk plans 15% expansion of U.S. work force

Friday, April 27, 2012 01:36 PM

Novo Nordisk, a global healthcare company headquartered in Denmark, is planning a nearly 15% expansion of its U.S. work force in 2012.

More... »

Jazz to acquire EUSA Pharma for $650 million

Friday, April 27, 2012 01:21 PM

Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the U.S. and U.K., for $650 million in cash and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze, achieving a specified U.S. net sales target in 2013.

More... »

Watson to acquire Actavis Group for $5.6 billion

Friday, April 27, 2012 01:02 PM

Watson Pharmaceuticals has decided to acquire privately held generics pharmaceutical company Actavis Group for an upfront payment of $5.6 billion. As a result, Watson will become the third largest global generics company with 2012 anticipated pro forma revenue of approximately $8 billion.

More... »

Frontage to develop AtheroNova clinical trial supplies

Friday, April 27, 2012 11:59 AM

Frontage, a global CRO based in Ecton, Penn., has signed an agreement to develop clinical trial supplies with AtheroNova, a biotech company focused on R&D of compounds to regress atherosclerotic plaque.

More... »

AstraZeneca’s CEO Brennan to retire

Friday, April 27, 2012 11:30 AM

Global biopharmaceutical company AstraZeneca has announced that CEO and board member David Brennan has decided to retire, effective June 1, 2012.

More... »

Targacept to reduce workforce, refocus company

Wednesday, April 25, 2012 02:47 PM

Targacept, a N.C.-based clinical-stage biopharmaceutical company developing novel NNR Therapeutics, plans to reduce its workforce by 65 employees, approximately 46%, as part of a strategic plan to focus the company's resources on its clinical programs and select preclinical opportunities.

More... »

Argos secures $25 million Series D financing for metastatic renal cell carcinoma

Wednesday, April 25, 2012 11:36 AM

Argos Therapeutics, a biopharmaceutical company of Durham, N.C., has secured a $25 million Series D financing to support the commencement of its phase III ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012.

More... »

Ipsen to relocate headquarters to New Jersey

Wednesday, April 25, 2012 10:59 AM

Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

More... »

Amgen to acquire Mustafa Nevzat of Turkey

Wednesday, April 25, 2012 10:22 AM

Amgen, a global biotech based in Thousand Oaks, Calif., will acquire 95.6% of shares in Mustafa Nevzat Pharmaceuticals (MN), a privately held Turkish pharmaceutical company, for approximately $700 million. The all-cash transaction will significantly expand Amgen's presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen.  

More... »

Merck announces Swiss efficiency program, closure of Geneva office

Wednesday, April 25, 2012 10:05 AM

Global pharmaceutical and chemical company Merck Serono has announced efficiency plans for its Swiss operations as part of its comprehensive transformation program—focused on addressing unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization.

More... »